{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Severe+Acute+Respiratory+Syndrome&page=3",
    "query": {
      "condition": "Severe Acute Respiratory Syndrome",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 259,
    "total_pages": 26,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Severe+Acute+Respiratory+Syndrome&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Severe+Acute+Respiratory+Syndrome&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-10T18:27:52.589Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04355494",
      "title": "SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19",
      "overall_status": "NO_LONGER_AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "COVID-19",
        "Pneumonia, Viral",
        "Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)"
      ],
      "interventions": [
        {
          "name": "eculizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2021-03-09",
      "last_synced_at": "2026-10-10T18:27:52.589Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • Boston, Massachusetts • Newton, Massachusetts + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Newton",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04355494"
    },
    {
      "nct_id": "NCT00006019",
      "title": "Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia",
        "Lung Cancer",
        "Lymphoma",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes",
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "azacitidine",
          "type": "DRUG"
        },
        {
          "name": "sodium phenylbutyrate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2000-05",
      "completion_date": "2003-08",
      "has_results": false,
      "last_update_posted_date": "2013-06-24",
      "last_synced_at": "2026-10-10T18:27:52.589Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00006019"
    },
    {
      "nct_id": "NCT04895475",
      "title": "Antibody Detection of Vaccine-Induced Secretory Effects",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Covid19",
        "Humoral Acquired Immunodeficiency",
        "Coronavirus",
        "SARS-CoV Infection"
      ],
      "interventions": [
        {
          "name": "SARS-CoV-2 vaccine",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Children's Hospital Medical Center, Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 61,
      "start_date": "2021-02-19",
      "completion_date": "2023-08-31",
      "has_results": false,
      "last_update_posted_date": "2025-07-30",
      "last_synced_at": "2026-10-10T18:27:52.589Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04895475"
    },
    {
      "nct_id": "NCT04452565",
      "title": "NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Coronavirus Infection",
        "Severe Acute Respiratory Infection",
        "Severe Acute Respiratory Syndrome Coronavirus 2"
      ],
      "interventions": [
        {
          "name": "Drug: NA-831",
          "type": "DRUG"
        },
        {
          "name": "NA-831 and Atazanavir",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "NA-831and Dexamethasone",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Atazanavir and Dexamethasone",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Biomed Industries, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 525,
      "start_date": "2022-06-15",
      "completion_date": "2023-12-15",
      "has_results": false,
      "last_update_posted_date": "2022-02-16",
      "last_synced_at": "2026-10-10T18:27:52.589Z",
      "location_count": 31,
      "location_summary": "Los Angeles, California • Orange, California • Palo Alto, California + 27 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04452565"
    },
    {
      "nct_id": "NCT05074719",
      "title": "Index Individuals in SARS-CoV-2 Prevention Research Studies (COVID-19 Index Individuals Companion Study)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "SARS-CoV-2 Infection",
        "COVID-19",
        "Coronavirus Infection",
        "SARS (Severe Acute Respiratory Syndrome)"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "10 Years and older"
      },
      "enrollment_count": 155,
      "start_date": "2020-12-10",
      "completion_date": "2021-10-31",
      "has_results": false,
      "last_update_posted_date": "2021-12-15",
      "last_synced_at": "2026-10-10T18:27:52.589Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05074719"
    },
    {
      "nct_id": "NCT05977192",
      "title": "Mobile Health-based Motivational Interviewing to Promote COVID-19 Vaccination",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Vaccination Hesitancy"
      ],
      "interventions": [
        {
          "name": "Standard MI",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Intensive MI",
          "type": "BEHAVIORAL"
        },
        {
          "name": "MOTIVACC",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Ecological momentary assessment (EMA) messages",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Oklahoma State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2024-04-01",
      "completion_date": "2025-03-01",
      "has_results": false,
      "last_update_posted_date": "2025-03-21",
      "last_synced_at": "2026-10-10T18:27:52.589Z",
      "location_count": 2,
      "location_summary": "Oklahoma City, Oklahoma • Stillwater, Oklahoma",
      "locations": [
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Stillwater",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05977192"
    },
    {
      "nct_id": "NCT05142306",
      "title": "A COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM, SC, or IV Routes to SARS-CoV-2 Uninfected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "SARS-CoV-2 Infection"
      ],
      "interventions": [
        {
          "name": "COVID-HIG",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Emergent BioSolutions",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "59 Years",
        "sex": "ALL",
        "summary": "18 Years to 59 Years"
      },
      "enrollment_count": 23,
      "start_date": "2021-12-07",
      "completion_date": "2022-05-31",
      "has_results": true,
      "last_update_posted_date": "2025-06-08",
      "last_synced_at": "2026-10-10T18:27:52.589Z",
      "location_count": 2,
      "location_summary": "Miami, Florida • Springfield, Missouri",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Springfield",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05142306"
    },
    {
      "nct_id": "NCT04421664",
      "title": "Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Corona Virus Infection",
        "SARS-CoV Infection",
        "Coronavirus"
      ],
      "interventions": [
        {
          "name": "Hydroxychloroquine",
          "type": "DRUG"
        },
        {
          "name": "Placebo oral tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "McGill University Health Centre/Research Institute of the McGill University Health Centre",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2020-03-25",
      "completion_date": "2020-08-17",
      "has_results": false,
      "last_update_posted_date": "2024-10-15",
      "last_synced_at": "2026-10-10T18:27:52.589Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04421664"
    },
    {
      "nct_id": "NCT05263921",
      "title": "Relative Bioavailability Study of PF-07321332/Ritonavir Oral Powder Relative to the Commercial Tablets in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Bioavailability"
      ],
      "interventions": [
        {
          "name": "PF-07321332/ritonavir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2022-03-10",
      "completion_date": "2022-05-19",
      "has_results": true,
      "last_update_posted_date": "2024-06-06",
      "last_synced_at": "2026-10-10T18:27:52.589Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05263921"
    },
    {
      "nct_id": "NCT04846010",
      "title": "Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Sequelae of; Infection",
        "Post Infection Glomerulonephritis",
        "Post-Infectious Peripheral Neuralgia",
        "Post-Infectious Disorder (Disorder)",
        "Post-Infectious Arthritis",
        "Post-Infectious Polyneuritis",
        "Post-Infectious Parkinsonism",
        "Post-Infectious Hypothyroidism",
        "Post Infectious Osteoarthritis",
        "Anxiety Disorders",
        "Depression",
        "Depression, Anxiety",
        "Depression, Bipolar",
        "Insomnia",
        "GERD",
        "Gastro Esophageal Reflux",
        "Hepatitis",
        "Glomerulonephritis"
      ],
      "interventions": [
        {
          "name": "PurWet",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "FurFat",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "PurApo",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "PurPhl",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "PurClo",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "PurInf",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Smoliv",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "All Natural Medicine Clinic, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 2000,
      "start_date": "2021-03-01",
      "completion_date": "2022-10-01",
      "has_results": false,
      "last_update_posted_date": "2021-05-26",
      "last_synced_at": "2026-10-10T18:27:52.589Z",
      "location_count": 1,
      "location_summary": "Rockville, Maryland",
      "locations": [
        {
          "city": "Rockville",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04846010"
    }
  ]
}